[Clinical efficacy observation of omalizumab on patients with moderate to severe allergic asthma for one year].

医学 奥马佐单抗 哮喘 支气管扩张剂 内科学 不利影响 肺功能测试 肺活量 过敏性哮喘 胃肠病学 免疫球蛋白E 麻醉 肺功能 肺 免疫学 抗体 扩散能力
作者
Yizhen Xu,Dexun Zhou,Ping Hu,Pihua Gong
出处
期刊:PubMed [National Institutes of Health]
卷期号:57 (3): 427-432
标识
DOI:10.3760/cma.j.cn112150-20221016-00998
摘要

To observe the symptom control, pulmonary function changes and safety of use of omalizumab in patients with moderate to severe allergic asthma for 1 year. A small sample self-controlled study before and after treatment was conducted to retrospective analysis involved 17 patients with moderate to severe asthma who received omalizumab therapy for 12 months in Peking University People's Hospital and Beijing Jishuitan Hospital from January 2020 to December 2021. The clinical symptoms and pulmonary function changes were compared before treatment, after 6 months and 12 months of treatment, and the clinical data such as the use of other drugs and adverse reactions were observed. Statistical data are collected using the median method, and non-parametric paired Wilcoxon analysis was used for pairwise comparison. Before treatment with omalizumab, the patients' FeNO value was 79(58, 121) ppb, and the total serum IgE was 228(150.5, 345.5) IU/ml. After 6 months of omalizumab therapy, the percent predicted value of the forced expiratory volume in 1 second (FEV1%) before inhaled bronchodilator increased from 86.70(82.65, 91.35)% to 90.90(87.70, 95.85)% (Z=-3.626, P<0.001). The FEV1%pred after inhaled bronchodilator increased from 92.60(85.75, 96.90)% to 94.30(89.95, 98.15)% (Z=-2.178, P=0.029). The absolute value of improvement in FEV1 decreased from 150(95, 210)ml to 50(20, 125) ml (Z=-2.796, P=0.005), and the improvement rate decreased from 6.60(3.80, 7.85)% to 1.90(0.75, 4.85)% (Z=-2.922, P=0.003). After 12 months of treatment, the FEV1%pred before inhaled bronchodilator further increased to 92.90 (91.60, 98.15)% (Z=-3.575, -2.818, and P<0.001, 0.005 compared with before treatment and 6 months after treatment, respectively). The FEV1%pred after inhaled bronchodilator increased to 96.80 (91.90, 101.25)% (Z=-3.622, -1.638, and P<0.001, 0.008 compared with before treatment and after 6 months of treatment, respectively). The absolute value of improvement in FEV1 was 70 (35, 120) ml (P=0.004, 0.842 before treatment and 6 months after treatment, respectively), and the improvement rate was 3.0(1.0, 5.0)% (Z=-2.960, -0.166, and P=0.003, 0.868, compared with before treatment and after 6 months of treatment, respectively). After 12 months of treatment, ACT increased from 13 (10.5, 18) before treatment to 24 (23, 25) (Z=-3.626,P<0.001). Only 1 patient experienced an injection site skin reaction during treatment. Therefore, after 6 months and 12 months of treatment with omalizumab, the patient's lung function improved and symptoms were relieved, which could effectively prevent the acute exacerbation of asthma. Omalizumab treatment is safe and well tolerated, and no effect on blood pressure and blood glucose was observed.为探讨使用奥马珠单抗治疗中重度过敏性哮喘患者的症状控制、肺功能变化及安全性。本研究采取小样本治疗前后自身对照研究的方法,回顾性分析2020年1月至2021年12月期间在北京大学人民医院和北京积水潭医院接受奥马珠单抗治疗12个月的17例中重度哮喘患者,比较患者治疗前、治疗6个月后和治疗12个月后临床症状、肺功能变化,并观察其他药物使用情况和不良反应等临床资料。数据采用中位数(四分位区间)即M(Q1,Q3)表示,对前后比较数据使用非参数配对Wilcoxon分析。结果显示,在使用奥马珠单抗治疗前,患者的FeNO值为79(58,121)ppb,血清总IgE为228(150.5,345.5)IU/ml。在使用奥马珠单抗治疗6个月后,患者吸入支气管扩张剂前的FEV1占预计值%由86.70(82.65,91.35)%上升至90.90(87.70,95.85)%(Z=-3.576,P<0.001),吸入支气管扩张剂后的FEV1占预计值%由92.60(85.75,96.90)%上升至94.30(89.95,98.15)%(Z=-2.178,P=0.029),FEV1改善绝对值由150(95,210)ml下降至50(20,125)ml(Z=-2.796,P=0.005),改善率由6.60(3.80,7.85)%下降至1.90(0.75,4.85)%(Z=-2.922,P=0.003)。经过治疗12个月后,患者吸入支气管扩张剂前的FEV1占预计值%进一步上升至92.90(91.60,98.15)%(与治疗前和治疗6个月后比较Z值分别为-3.575、-2.818,P分别为<0.001、0.005),吸入支气管扩张剂后的FEV1占预计值%上升至96.80(91.90,101.25)%(与治疗前和治疗6个月后比较Z值分别为-3.622、-2.638,P分别为<0.001、0.008),FEV1改善绝对值为70(35,120)ml(与治疗前和治疗6个月后比较Z值分别为-2.915、-1.999,P分别为0.004、0.842),改善率为3.0(1.0,5.0)%(与治疗前和治疗6个月后比较Z值分别为-2.960、-0.166,P分别为0.003、0.868)。治疗12个月后ACT由治疗前的13(10.5,18)提高到24(23,25)(Z=-3.626,P<0.001)。患者在治疗过程中,仅有1例出现注射部位皮肤反应。综上,使用奥马珠单抗治疗6个月和12个月时,肺功能得以持续改善,患者哮喘症状明显得以控制,并能有效预防哮喘急性发作。同时,奥马珠单抗治疗的安全性和耐受性较好,未发现奥马珠单抗对患者血压、血糖的影响。.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
jeff发布了新的文献求助10
1秒前
1秒前
1秒前
2秒前
庾傀斗发布了新的文献求助10
3秒前
Orange的应助被川里九樱采纳,获得10
3秒前
留胡子的黑夜完成签到,获得积分10
3秒前
3秒前
Jako完成签到 ,获得积分10
4秒前
小拉卡咪发布了新的文献求助10
4秒前
tanfor完成签到 ,获得积分10
5秒前
tom发布了新的文献求助10
5秒前
秋风的应助被chuhan采纳,获得10
5秒前
LIN发布了新的文献求助30
6秒前
molihuakai的应助被科研通管家采纳,获得10
7秒前
秋水关注了科研通微信公众号
7秒前
7秒前
桐桐的应助被科研通管家采纳,获得10
7秒前
Lucas的应助被科研通管家采纳,获得10
8秒前
完美世界的应助被科研通管家采纳,获得10
8秒前
CipherSage的应助被科研通管家采纳,获得10
8秒前
orixero的应助被科研通管家采纳,获得10
8秒前
无花果的应助被科研通管家采纳,获得10
8秒前
8秒前
8秒前
8秒前
zp的应助被科研通管家采纳,获得20
8秒前
FashionBoy的应助被科研通管家采纳,获得10
8秒前
9秒前
minting完成签到 ,获得积分10
9秒前
11秒前
11秒前
11秒前
11秒前
茉莉花发布了新的文献求助30
12秒前
carol7298发布了新的文献求助10
12秒前
fantasy的应助被小祝没吃饱采纳,获得10
14秒前
14秒前
Dyying发布了新的文献求助10
14秒前
经十路以东的应助被MMLi采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194041
求助须知:如何正确求助?哪些是违规求助? 9579979
关于积分的说明 21868799
捐赠科研通 7793641
什么是DOI,文献DOI怎么找? 3437477
关于科研通互助平台的介绍 2560942
邀请新用户注册赠送积分活动 2484251